Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 4/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
| ▸ | PPARA | Q07869 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4481984 | 1.00 | NR1H4 (0.38) | NR1H4MAPTKDM4EHPSEPPARD | |
| SCHEMBL4492234 | 0.93 | NR1H4 (0.38) | NR1H4MAPTKDM4EHPSEPPARD | |
| SCHEMBL4492239 | 0.93 | NR1H4 (0.38) | NR1H4MAPTKDM4EHPSEPPARD | |
| SCHEMBL228141 | 0.91 | HSPH1 (0.42) | NR1H4MAPTKDM4EPPARGPPARA | |
| SCHEMBL228142 | 0.91 | HSPH1 (0.42) | NR1H4MAPTKDM4EPPARGPPARA | |
| SCHEMBL4500507 | 0.91 | KDM4E (0.41) | NR1H4MAPTKDM4EMEN1KMT2A | |
| SCHEMBL4500501 | 0.91 | KDM4E (0.41) | NR1H4MAPTKDM4EMEN1KMT2A | |
| SCHEMBL4501934 | 0.90 | NR1H4 (0.38) | NR1H4KDM4EHPSEPPARDPPARG | |
| SCHEMBL4501927 | 0.90 | NR1H4 (0.38) | NR1H4KDM4EHPSEPPARDPPARG | |
| SCHEMBL4497348 | 0.89 | NR1H4 (0.38) | NR1H4MAPTKDM4EHPSEPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | NR1H4 544/4885MAPT 545/4885KDM4E 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.